Clinical Trial

Long-Term Feedback Effect of FGM in Newly-Diagnosed T2D Patients

Study acronym: DIAFLASH
Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 18, 2025 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This clinical trial aims to evaluate the educational training of 12-weeks using flash glucose monitoring (FGM) FreeStyle Libre2 (FSL2; Abbott Diabetes Care Inc., Alameda, CA, USA) in newly- diagnosed T2D subjects who are treated with metformin in term of sustained improvement in glycemic variability (TIR) after the discontinuation of FGM compared to self-monitoring of blood glucose (SMBG). This clinical trial also aim to explore which frequency of sensor wear at the diagnosis is more effective in achieving a sustained improvement in TIR after the FGM discontinuation over time.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-10-18.
Status change: Recruiting → Active, Not Recruiting 2025-02-14
Trial Details
NCT Number NCT06098040
Lead Sponsor Campus Bio-Medico University
Conditions Type 2 Diabetes
Enrollment 42 participants
Start Date 2023-09-22
Primary Completion 2025-06-30 (estimated)
Study Completion 2025-09-30 (estimated)
Updated on ClinicalTrials.gov 2025-02-18